ASAMAX

This brand name is authorized in Italy, New Zealand, Poland

Active ingredients

The drug ASAMAX contains one active pharmaceutical ingredient (API):

1 Mesalazine
UNII 4Q81I59GXC - MESALAMINE

Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Read about Mesalazine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A07EC02 Mesalazine A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07E Intestinal antiinflammatory agents → A07EC Aminosalicylic acid and similar agents
Discover more medicines within A07EC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: IT Agenzia del Farmaco Identifier(s): 034298024, 034298051
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 12211, 12213
Country: PL Rejestru Produktรณw Leczniczych Identifier(s): 100127789, 100127795, 100127803, 100127810

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.